• 

  Leqembi Vs. Kisunla: An Alzheimer’s Drug Point-by-Point Comparison
• 

  NIH Activities Grind to Halt Under Trump Comms Freeze
• 

  Some Trial Volunteers Had Higher Risk of Brain Bleeds. Here’s Why Drugmakers Didn’t Tell Them
• 

  Axsome Asks FDA to Approve Questionable Alzheimer’s Agitation Drug
• 

  How a Condition Transmitted by Cannibalism Shed New Light on Brain Diseases
• 

  Quebec Allows People to Break Federal Laws Around Dementia and Medical Euthanasia
• 

  Alzheimer’s Drugmaker Athira Shells Out $4 Million In DOJ Settlement
• 

  STUDY: Wildfire Smoke Exposure Ups Dementia Risk
• 

  Are Sleep Drugs Safe for People with Dementia?
• 

  U.S. Senate Passes Act Tripling Funding to State and Local Dementia Programs
• 

  Diagnostic Drama: Clinicians Argue Dueling Definitions of Alzheimer’s
• 

  How Bad Is Fraud in Alzheimer’s Research? Q&A With Neurologist-Sleuth Matthew Schrag
• 

  The Brain’s Blood Vessels May Be Driving Cognitive Decline in Women
• 

  Alzheimer’s Treatment Plot Twist: When (Healthy) Amyloid Goes Up, Cognitive Decline Slows Down
• 

  Cassava Drug Simufilam Fails First Phase 3 Trial, Halts Second Phase 3 Trial

Previous121314Next